Transform Diabetes Study v1.0

  • Research type

    Research Study

  • Full title

    The Transform Diabetes Study: A mixed-methods study to evaluate the acceptability and potential clinical impact of a choice of dietary interventions delivered through digital group or 1 to 1 care to support weight loss and improve glycaemic control in adults with type 2 diabetes within an ethnically diverse population

  • IRAS ID

    295915

  • Contact name

    Lucy Jones

  • Contact email

    Lucy.jones@oviva.com

  • Sponsor organisation

    Oviva UK

  • Clinicaltrials.gov Identifier

    NCT05648903

  • Duration of Study in the UK

    2 years, 3 months, 30 days

  • Research summary

    The Transform Diabetes Study proposes to evaluate the acceptability and potential clinical impact of a choice of diets in adults with type 2 diabetes in a multicultural community. Participants will be allocated to receive their care either through a remote group programme or a remote 1 to 1 programme which will help us to understand if either delivery option is more effective or acceptable to patients. The aim of treatment is to achieve weight loss, improve diabetes control and in some cases put diabetes into remission (reversing their diabetes). The study plans to enrol 120 patients from five GP practices in Southwark, London. Different types of information will be collected in aim to answer these questions such as collecting information through surveys and interviews alongside assessment of clinical outcomes to determine how successful these interventions have been and how these interventions could be improved in the future. The study will also seek to explore the perceptions and experiences of staff at the GP practices, commissioners and those who are managing the study to assess how the programme went and how things could be improved with the aim of improving patient services in the future.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    21/NW/0214

  • Date of REC Opinion

    2 Sep 2021

  • REC opinion

    Further Information Favourable Opinion